Jiangsu Hengrui Pharmaceuticals Co.,Ltd (SHA:600276)
China · Delayed Price · Currency is CNY 51.45
+0.50 (0.98%)
May 21, 2026, 3:00 PM CST
SHA:600276 Revenue
Jiangsu Hengrui Pharmaceuticals Co.,Ltd had revenue of 8.14B CNY in the quarter ending March 31, 2026, with 12.98% growth. This brings the company's revenue in the last twelve months to 32.56B, up 11.55% year-over-year. In the year 2025, Jiangsu Hengrui Pharmaceuticals Co.,Ltd had annual revenue of 31.63B with 13.02% growth.
Revenue (ttm)
32.56B
Revenue Growth
+11.55%
P/S Ratio
10.38
Revenue / Employee
1.58M
Employees
20,602
Market Cap
337.88B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 31.63B | 3.64B | 13.02% |
| Dec 31, 2024 | 27.98B | 5.16B | 22.63% |
| Dec 31, 2023 | 22.82B | 1.54B | 7.26% |
| Dec 31, 2022 | 21.28B | -4.63B | -17.87% |
| Dec 31, 2021 | 25.91B | -1.83B | -6.59% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Huadong Medicine | 44.06B |
| Shanghai Fosun Pharmaceutical (Group) | 42.31B |
| Yunnan Baiyao Group Co.,Ltd | 41.95B |
| China Resources Sanjiu Medical & Pharmaceutical | 32.88B |
| Humanwell Healthcare (Group) | 23.93B |
| Zhejiang NHU Company | 23.11B |
| Beijing Tongrentang | 16.64B |
| Changchun High-Tech Industry (Group) | 11.67B |
Jiangsu Hengrui Pharmaceuticals Co.,Ltd News
- 4 days ago - BMY: Bristol Myers Squibb and Hengrui Pharma Strike $15.2B Licensing Deal - GuruFocus
- 6 days ago - Big Pharma deepens China drug partnerships amid biotech boom - CNBC
- 6 days ago - Weekly Buzz: Lilly Posts Positive Trial Data, Rigel Licenses PROTAC Drug, BMY Strikes $15.2B Deal - Nasdaq
- 9 days ago - Bristol Myers Squibb (BMY) Partners with Hengrui Pharma for $15.2B R&D Collaboration - GuruFocus
- 4 weeks ago - Jiangsu Hengrui Pharmaceuticals Co.,Ltd Quarterly report: Q1 2026 - Filings
- 4 weeks ago - Jiangsu Hengrui Pharmaceuticals Co.,Ltd Quarterly report: Q1 2026 - Filings
- 2 months ago - Jiangsu Hengrui Pharmaceuticals Co.,Ltd Annual report: H2 2025 - Filings
- 2 months ago - Jiangsu Hengrui Pharmaceuticals Co.,Ltd Earnings release: H2 2025 - Filings